Gabriel Bonnell

Gabriel Bonnell, MD

Assistant Professor

Department: MD – VASCULAR NEUROLOGY
Business Phone: (352) 273-5550
Business Email: gbonnell@ufl.edu

About Gabriel Bonnell

Dr. Bonnell received his B.S with a double major in Biology and Psychology with a Chemistry minor from his home state at the University of Utah in Salt Lake City. He stayed at the University of Utah to complete his medical training in 2014. Dr. Bonnell completed his first 2 years of training at the Medical University of South Carolina in Charleston, and completed his last 2 years of residency at the Medical College of Wisconsin in Milwaukee. He also completed his Fellowship training at the Medical College of Wisconsin.

Dr. Bonnell’s medical interests include acute management of Ischemic stroke, as well as teaching fellows, residents, and medical students.

When not working, Dr. Bonnell’s hobbies include spending time with his family, reading, brewing beer, playing poker, running, hiking, and generally enjoying the outdoors. His goals are to visit every national park and to eventually see the northern lights.

Teaching Profile

Courses Taught
2021
MDC7800 Neurology Clerkship
2022-2024
PAS5020 Intro to Medicine 2
2023-2024
BMS6020 Clinical Neuroscience

Clinical Profile

Specialties
  • Vascular Neurology
Areas of Interest
  • Stroke

Publications

2023
Small-vessel disease in the brain.
American heart journal plus : cardiology research and practice. 27 [DOI] 10.1016/j.ahjo.2023.100277. [PMID] 38511094.
2023
Use of Stroke Alert Sticker in the Field Decreases Time to Acute Interventions for Ischemic Stroke Patients.
The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses. 55(6):194-198 [DOI] 10.1097/JNN.0000000000000728. [PMID] 37931083.
2022
Clinical Reasoning: A Case of Acute Akinetic Mutism and Encephalopathy.
Neurology. 99(17):761-766 [DOI] 10.1212/WNL.0000000000201207. [PMID] 36008149.

Grants

May 2023 ACTIVE
A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA
Role: Principal Investigator
Funding: IQVIA Holdings via BAYER HEALTHCARE PHARMACEUTICALS
Sep 2021 – Sep 2021
Validation of Early Prognostic Data for Recovery Outcomes after Stroke for Future, Higher Yield Trials (VERIFY)
Role: Principal Investigator
Funding: UNIV OF CINCINNATI via NATL INST OF HLTH NINDS

Contact Details

Phones:
Business:
(352) 273-5550
Emails:
Business:
gbonnell@ufl.edu
Addresses:
Business Mailing:
PO Box 103715
GAINESVILLE FL 32611
Business Street:
1329 SW 16TH ST RM 1160
GAINESVILLE FL 32608